Biology | Chemicals and Drugs | Medical Pharmacology | Pharmacy and Pharmaceutical Sciences
Description, Abstract, or Artist's Statement
Varenicline was approved in 2006 by the FDA as an effective smoking cessation drug. Varenicline was designed to bind with α4β2 nicotinic acetylcholine receptors (nAChR) to work as both an agonist and antagonist. Other drugs like nicotine replacement therapies (NRTs) have also contributed to the decreasing rate of active smokers in the United States. The mechanisms of varenicline and its role in addiction are reviewed in this paper. With NRTs and recent trends in electronic smoking devices, nicotine dependence is still a cause for concern due to studies connecting nicotine with cell proliferation and heart disease.
Augustana Digital Commons Citation
DeVoss, Marley Vea. "Smoking Cessation Treatments Varenicline (Chantix®️), NRTs, and Nicotine Dependence" (2019). Biology: Student Scholarship & Creative Works.